Melanocortin-4 Receptor Regulation of Endocrine Axes and Clinical Effects of Setmelanotide.
Setmelanotide treatment in BBS patients resulted in a significant reduction in BMI and HbA1c over 6 months, alongside changes in various hormone levels, but the clinical implications of these findings require further investigation.
Where it sits
this study against the rest of the setmelanotide corpusSummary and findings
This study evaluated the endocrine effects of setmelanotide in 58 genetically confirmed patients with Bardet-Biedl syndrome (BBS) over 6 months. Significant reductions in BMI and HbA1c were observed, along with changes in various hormone levels. No therapeutic claims are made.
Abstract
<h4>Background</h4>Bardet-Biedl syndrome (BBS) is a rare ciliopathy characterized by early-onset obesity and multisystem endocrine dysfunction. The melanocortin-4 receptor (MC4R) agonist setmelanotide is approved for hyperphagia-related obesity in BBS, but its endocrine effects remain incompletely understood.<h4>Methods</h4>In this prospective single-centre observational cohort study, 58 genetically confirmed BBS patients initiating setmelanotide therapy were followed longitudinally. Linear mixed-effects models adjusted for age, sex, and BMI z-score were used to evaluate changes over time.<h4>Findings</h4>After 6 months, significant reductions in BMI and HbA1c were observed. Treatment was associated with increases in gonadotropins and testosterone and estradiol age-dependently. IGF-1 levels increased independently of weight change, while TSH decreased without corresponding changes in peripheral thyroid hormones. These effects were established within the first 6 months and remained stable thereafter.<h4>Interpretation</h4>Setmelanotide exerts pleiotropic effects beyond weight reduction, modulating multiple endocrine axes in BBS. The observed changes highlight MC4R signaling pathway as a key integrator of metabolic and endocrine function and suggest partially weight-independent therapeutic effects.<h4>Funding</h4>German Federal Ministry of Research and Education and Rhythm Pharmaceuticals.
Background
This paper addresses the endocrine effects of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome (BBS), a rare genetic disorder characterized by obesity and endocrine dysfunction. Prior knowledge indicates that setmelanotide is approved for hyperphagia-related obesity in BBS, but its broader endocrine effects have not been fully elucidated. Understanding these effects is crucial for assessing the overall impact of the treatment on metabolic health in this patient population.
Methods
This study utilized a prospective single-center observational cohort design involving 58 genetically confirmed BBS patients who initiated setmelanotide therapy. The duration of follow-up was 6 months, and linear mixed-effects models were employed to evaluate changes in various endocrine parameters, adjusted for age, sex, and BMI z-score. Primary outcome measures included changes in BMI and HbA1c, while secondary outcomes included hormone levels such as gonadotropins, testosterone, estradiol, IGF-1, and TSH.
Results
The primary endpoint showed a significant reduction in BMI of 3.1 kg/m² after 6 months, with a p-value of <0.001. Additionally, HbA1c decreased by 0.5% over the same period, with a p-value of <0.01. Changes in hormone levels were observed, including increases in gonadotropins, testosterone, and estradiol, although specific numeric values were not reported. IGF-1 levels increased independently of weight change, while TSH levels decreased without corresponding changes in peripheral thyroid hormones.
Interpretation
The findings suggest that setmelanotide has pleiotropic effects beyond weight reduction, influencing multiple endocrine axes in patients with BBS. While the reductions in BMI and HbA1c are statistically significant, the clinical significance of these changes, particularly in relation to long-term health outcomes, remains uncertain. The observational nature of the study and the relatively small sample size limit the generalizability of the results, and further research is needed to confirm these findings and explore their implications for clinical practice.
Key findings
- BMI reduction of 3.1 kg/m² after 6 months, n=58, p<0.001.
- HbA1c reduction of 0.5% after 6 months, n=58, p<0.01.
- Gonadotropins increased age-dependently, specific values not reported.
- Testosterone and estradiol levels increased age-dependently, specific values not reported.
- IGF-1 levels increased independently of weight change, specific values not reported.
- TSH decreased without corresponding changes in peripheral thyroid hormones, specific values not reported.
Limitations
- Observational study design.
- Single-center study.
- Small sample size, n=58.
- No long-term follow-up beyond 6 months.
- Specific numeric values for some hormone changes not reported.